Rapport Therapeutics (RAPP) Assets Average (2024 - 2026)

Rapport Therapeutics (RAPP) has reported Assets Average for 3 consecutive years, with $505.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 63.7% year-over-year to $505.0 million; the TTM figure through Mar 2026 stood at $505.0 million (up 63.7% YoY), while the FY2025 annual figure was $413.7 million, up 75.9% from the prior year.
• Assets Average declined to $505.0 million in Q1 2026 per RAPP's latest filing, from $523.9 million in the prior quarter.
• Across five years, Assets Average topped out at $523.9 million in Q4 2025 and bottomed at $293.8 million in Q2 2025.
• Historically, Assets Average has averaged $386.2 million across 3 years, with a median of $338.6 million in 2024.
• Annual changes were most pronounced in 2025 — Assets Average advanced 21.2% — and 2026, when it surged 63.7%.
• Rapport Therapeutics' Assets Average stood at $323.0 million in 2024, then jumped by 62.17% to $523.9 million in 2025, then fell by 3.6% to $505.0 million in 2026.
• Business Quant data shows RAPP's Assets Average at $505.0 million in Q1 2026, $523.9 million in Q4 2025, and $410.4 million in Q3 2025.